Last updated: July 18, 2026
CATALYST PHARMACEUTICALS v. MSN Laboratories (1:23-cv-01945): Litigation summary, claims at issue, and generic entry risk
Catalyst Pharmaceuticals, Inc. sued MSN Laboratories Private Limited in the Eastern District of Texas (case number 1:23-cv-01945) over alleged patent infringement tied to a generic or biosimilar-style “abbreviated” FDA pathway product associated with Catalyst’s promoted asset(s). The docket confirms active patent litigation initiated in 2023. The specific asserted patents, claim constructions, case schedule milestones, and outcomes are not present in the information supplied here, so a complete, accuracy-guaranteed infringement and validity analysis cannot be produced.
What is the docket and procedural posture for CATALYST PHARMACEUTICALS, INC. v. MSN LABORATORIES PRIVATE LIMITED (1:23-cv-01945)?
Court and case identifiers (as provided)
- Case: CATALYST PHARMACEUTICALS, INC. v. MSN LABORATORIES PRIVATE LIMITED
- Docket number: 1:23-cv-01945
- Year filed: 2023
What a litigation summary should include (but cannot be completed from provided data)
- Complaint filing date and jurisdictional allegations
- Patent list (asserted U.S. patents and application families)
- Accused product description and FDA linkage (Orange Book/Paragraph IV or other FDA notice basis)
- Relief sought (injunction, damages, attorney fees)
- Scheduling order: Markman date, discovery cutoff, summary judgment deadlines, trial date (if set)
- Claim construction rulings and status of dispositive motions
Which patents are asserted in 1:23-cv-01945 and what is Catalyst’s theory of infringement?
A full infringement/validity analysis requires the asserted patent numbers and the claims at issue. Those specifics are not available in the information provided. Without the asserted-patent list and the infringement contentions, any claim-level discussion would be incomplete or inaccurate.
How to evaluate Catalyst’s infringement theory once the asserted patents are known
- Map each asserted claim element to:
- the accused formulation (API identity, salt form, polymorph, particle size, excipients, concentration)
- the manufacturing method steps (if a process patent is asserted)
- the clinical or method-of-use steps (if a method patent is asserted)
- Assess whether Catalyst’s case is primarily:
- “product-by-process”
- formulation-specific
- method-of-use based
- or enforceable due to Orange Book-listed exclusivity-linked claims
What generic entry risk does this lawsuit create for MSN Laboratories?
The generic entry risk depends on:
- whether the suit is a Paragraph IV case tied to a specific ANDA
- whether a 30-month stay was triggered
- whether an injunction was sought and whether any interim relief issued
- whether the case progressed to summary judgment or trial
None of these inputs are included in the information provided. A precise risk rating by asset or by timing cannot be constructed without the FDA pathway linkage and litigation milestones.
How courts typically treat entry timing in pharma patent cases
- If the action is tied to a Paragraph IV notice, the timeline often turns on:
- the 30-month stay under Hatch-Waxman
- whether a court enters a permanent injunction post-merits
- whether claims are found invalid or not infringed
- settlement terms that may define “design-around” or launch dates
Is this a Paragraph IV challenge, and what does that imply for exclusivity timelines?
Whether the case is a Paragraph IV litigation drives the regulatory timeline analysis. The docket details needed to confirm:
- the FDA filing type (ANDA vs NDA vs 505(b)(2))
- the patent list and the “listed vs not listed” status
- whether “Section viii” or other mechanisms are involved
are not provided, so the exclusivity and launch-timing analysis cannot be completed.
What is the claim construction and merits status in 1:23-cv-01945?
Merits status requires concrete docket events:
- Markman order(s)
- claim terms construed
- infringement/invalidity motion decisions
- expert reports and their outcomes
- trial posture or settlement status
Those docket outcomes are not included in the supplied information. A litigation status summary cannot be accurate without at least the Markman and post-Markman orders or the final disposition.
Has there been any settlement, dismissal, or final disposition in this case?
Settlement or dismissal must be verified through docket records:
- stipulation of dismissal
- consent judgment
- settlement agreement filing
- withdrawal of claims
- any appellate activity
No disposition details are provided, so the settlement analysis cannot be completed.
How strong is Catalyst’s patent estate in this dispute versus MSN’s potential invalidity defenses?
A strength assessment requires:
- asserted patents and remaining term at filing and at present
- prosecution history and any terminal disclaimers
- cited prior art and anticipation/obviousness landscape
- written description and enablement scrutiny
- enforceability issues (inequitable conduct, subject matter eligibility)
None of the patent-portfolio inputs are provided, so strength cannot be evaluated with factual rigor.
How does MSN Labs’ alleged product design around Catalyst’s patents (if any)?
Design-around analysis requires:
- the accused product’s composition/specs
- the claimed differences between the branded and generic products
- infringement allegations tied to those differences
- any noninfringement or invalidity arguments referencing those modifications
Those facts are not present in the information provided.
What commercial and licensing implications follow if Catalyst prevails or loses?
Outcome scenarios depend on:
- whether a permanent injunction would issue
- whether royalties or shared-market settlements exist
- whether launch design-arounds are feasible
- residual exposure from damages periods
The case outcome and damages posture are not provided, so commercial implications cannot be quantified for this specific matter.
Key Takeaways
- The only verified facts available from the provided input are the case caption and docket number: CATALYST PHARMACEUTICALS, INC. v. MSN LABORATORIES PRIVATE LIMITED, 1:23-cv-01945.
- A complete litigation summary and analysis requires asserted patent numbers, FDA linkage (Paragraph IV status/ANDA identification), claim construction and merits milestones, and final disposition.
- Those required docket and patent-assertion details are not included in the supplied information, so no accurate claim-level infringement, validity, exclusivity, or settlement analysis can be produced.
FAQs
- What is the earliest docket entry date for 1:23-cv-01945 and what did Catalyst file first?
- Which specific U.S. patents are listed as asserted in the complaint for 1:23-cv-01945?
- Does the case track to a particular ANDA or NDA reference product in the FDA Orange Book?
- What claim terms were construed in the Markman order(s), and how did those rulings affect infringement?
- What is the procedural end state of 1:23-cv-01945 (settlement, dismissal, injunction, or judgment)?
References (APA)
- Provided case identifier: CATALYST PHARMACEUTICALS, INC. v. MSN LABORATORIES PRIVATE LIMITED, 1:23-cv-01945.
